Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...
Medication non-adherence among people with chronic obstructive pulmonary disease (COPD) is a result of lack of affordability and lack of knowledge about medications, among other factors, according ...
Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab ...
Jan. 8 -- THURSDAY, Jan. 7 (HealthDay News) -- New research suggests that the drug ipratropium bromide (Atrovent), used widely among patients who have chronic obstructive pulmonary disease (COPD), may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results